Viral Hepatitis

Viral Hepatitis Prevention Coordinators, a Vital CDC Program Helping to Achieve the Goals of the Viral Hepatitis Action Plan

CDC Logo

Viral Hepatitis Prevention Coordinators (VHPCs) are vital to the implementation of the nation’s Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis, and ultimately, achievement of 3 of the national goals of reducing viral hepatitis transmission and disease: Increase the proportion of persons who are aware of their hepatitis B virus (HBV) infection,…

Viral Hepatitis Issues Examined at 2014 American Public Health Association (APHA) Annual Meeting


Hepatitis B and C were among the important public health issues examined at the recent annual meeting of the American Public Health Association (APHA) . The annual meeting, held November 14-19, 2014 in New Orleans, Louisiana, is one of the nation’s largest gatherings of public health professionals, including clinicians, researchers, policy makers, students, and others committed…

Looking Ahead to 2015


As 2014 comes to a close and we prepare to celebrate the potential of the new year, Dr. Ronald Valdiserri, Deputy Assistant Secretary for Health, Infectious Diseases, shares his thoughts on the year ahead in this video message. Dr. Valdiserri, who leads efforts to implement the National HIV/AIDS Strategy and the Viral Hepatitis Action Plan,…

2014 Viral Hepatitis Year-in-Review and Looking to 2015

Ronald Valdiserri

2014 has been a year of both opportunities and challenges in the fight against viral hepatitis. In May, the World Health Assembly passed a new resolution  [PDF 151 KB] on viral hepatitis, urging member states to develop and implement coordinated, national strategies for preventing, diagnosing and treating viral hepatitis.  Our nation’s own comprehensive viral hepatitis strategy,…

FDA approves Viekira Pak to treat hepatitis C


The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis. Hepatitis C is a viral disease that causes inflammation of the liver that…

Two New Hepatitis C Resources Support Expanding Provider Capacity

Ronald Valdiserri

Two professional medical societies have recently launched initiatives to support a wider variety of health care providers in adapting to new roles and opportunities resulting from the rapidly evolving arena of hepatitis C (HCV) screening, diagnosis, and treatment. As the Viral Hepatitis Action Plan observes, providers at every level in the healthcare system can play…

The 2014 Liver Meeting – Report on Viral Hepatitis Coverage at the American Association for the Study of Liver Diseases (AASLD) Meeting


Last month, the American Association for the Study of Liver Diseases (AASLD) annual meeting  (The Liver Meeting®) took place, convening nearly 10,000 physicians, surgeons, researchers, allied health professionals and advocates from around the world to discuss the natural history, prevention, and cure of liver diseases. With the availability of new all-oral, direct-acting agents (DAAs), there…

Revised Hepatitis C (HCV)/HIV Coinfection Section of the Adult and Adolescent Antiretroviral Treatment Guidelines Released

Last week, the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents announced the release of the updated “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.” As described in What’s New in the Guidelines, this interim revision of the guidelines features a revised section on Hepatitis C (HCV)/HIV Coinfection that emphasizes…